Multiple HER2-targeting agents have since been developed, including antibody therapies such as pertuzumab, and small-molecule TKIs, such as lapatinib and neratinib, the only two TKIs approved for treatment of HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.